APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Therapeutic

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.

Selected research

Market Outlook & Growth Opportunities

Global Malignant Mesothelioma Therapeutic Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Therapeutic Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Therapeutic Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Therapeutic Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Therapeutic Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.

The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Read the full market overview

This report provides an overview of the global Malignant Mesothelioma Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Malignant Mesothelioma Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Malignant Mesothelioma Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Malignant Mesothelioma Therapeutic market.

Malignant Mesothelioma Therapeutic Segment by Company

Eli Lilly

Teva

Sanofi

Bristol-Myers Squibb

Pfizer

Roche

Merck

Ono Pharmaceutical

Mylan

Fresenius Kabi

Sun Pharmaceuticals

Malignant Mesothelioma Therapeutic Segment by Type

Pemetrexed

Cisplatin

Others

Malignant Mesothelioma Therapeutic Segment by Application

Pleural Mesothelioma

Peritoneal Mesothelioma

Others

Malignant Mesothelioma Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Malignant Mesothelioma Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Malignant Mesothelioma Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Malignant Mesothelioma Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Malignant Mesothelioma Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Malignant Mesothelioma Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Malignant Mesothelioma Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Malignant Mesothelioma Therapeutic industry.

Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Malignant Mesothelioma Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Malignant Mesothelioma Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Malignant Mesothelioma Therapeutic Industry Trends Table 2. Malignant Mesothelioma Therapeutic Industry Drivers Table 3. Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges Table 4. Malignant Mesothelioma Therapeutic Industry Restraints Table 5. Global Malignant Mesothelioma Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Malignant Mesothelioma Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Malignant Mesothelioma Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Malignant Mesothelioma Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Malignant Mesothelioma Therapeutic Company, Product Type & Application Table 10. Global Malignant Mesothelioma Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Malignant Mesothelioma Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pemetrexed Table 15. Significant Companies of Cisplatin Table 16. Significant Companies of Others Table 17. Global Malignant Mesothelioma Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Malignant Mesothelioma Therapeutic Sales Value Share by Type (2021-2026) Table 21. Global Malignant Mesothelioma Therapeutic Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pleural Mesothelioma Table 23. Significant Companies of Peritoneal Mesothelioma Table 24. Significant Companies of Others Table 25. Global Malignant Mesothelioma Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Malignant Mesothelioma Therapeutic Sales Value Share by Application (2021-2026) Table 29. Global Malignant Mesothelioma Therapeutic Sales Value Share by Application (2027-2032) Table 30. Global Malignant Mesothelioma Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Malignant Mesothelioma Therapeutic Sales Value Share by Region (2021-2026) Table 33. Global Malignant Mesothelioma Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Malignant Mesothelioma Therapeutic Sales Value Share by Region (2027-2032) Table 35. Global Malignant Mesothelioma Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Malignant Mesothelioma Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Malignant Mesothelioma Therapeutic Sales Value Market Share by Country (2021-2026) Table 38. Global Malignant Mesothelioma Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Malignant Mesothelioma Therapeutic Sales Value Market Share by Country (2027-2032) Table 40. Eli Lilly Company Information Table 41. Eli Lilly Business Overview Table 42. Eli Lilly Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio Table 44. Eli Lilly Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Teva Malignant Mesothelioma Therapeutic Product Portfolio Table 49. Teva Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sanofi Malignant Mesothelioma Therapeutic Product Portfolio Table 54. Sanofi Recent Development Table 55. Bristol-Myers Squibb Company Information Table 56. Bristol-Myers Squibb Business Overview Table 57. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio Table 59. Bristol-Myers Squibb Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Malignant Mesothelioma Therapeutic Product Portfolio Table 64. Pfizer Recent Development Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Roche Malignant Mesothelioma Therapeutic Product Portfolio Table 69. Roche Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck Malignant Mesothelioma Therapeutic Product Portfolio Table 74. Merck Recent Development Table 75. Ono Pharmaceutical Company Information Table 76. Ono Pharmaceutical Business Overview Table 77. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio Table 79. Ono Pharmaceutical Recent Development Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mylan Malignant Mesothelioma Therapeutic Product Portfolio Table 84. Mylan Recent Development Table 85. Fresenius Kabi Company Information Table 86. Fresenius Kabi Business Overview Table 87. Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio Table 89. Fresenius Kabi Recent Development Table 90. Sun Pharmaceuticals Company Information Table 91. Sun Pharmaceuticals Business Overview Table 92. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio Table 94. Sun Pharmaceuticals Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Therapeutic Product Image Figure 2. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Malignant Mesothelioma Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pemetrexed Image Figure 8. Cisplatin Image Figure 9. Others Image Figure 10. Global Malignant Mesothelioma Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Malignant Mesothelioma Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Malignant Mesothelioma Therapeutic Sales Value Share by Type (2021-2032) Figure 13. Pleural Mesothelioma Image Figure 14. Peritoneal Mesothelioma Image Figure 15. Others Image Figure 16. Global Malignant Mesothelioma Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Malignant Mesothelioma Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Malignant Mesothelioma Therapeutic Sales Value Share by Application (2021-2032) Figure 19. Global Malignant Mesothelioma Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Malignant Mesothelioma Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Malignant Mesothelioma Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 22. North America Malignant Mesothelioma Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Malignant Mesothelioma Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Malignant Mesothelioma Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Malignant Mesothelioma Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Malignant Mesothelioma Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Malignant Mesothelioma Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 28. South America Malignant Mesothelioma Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Pemetrexed
  • Cisplatin
  • Others
Applications
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Others
Companies covered
  • Eli Lilly
  • Teva
  • Sanofi
  • Bristol-Myers Squibb
  • Pfizer
  • Roche
  • Merck
  • Ono Pharmaceutical
  • Mylan
  • Fresenius Kabi
  • Sun Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Malignant Mesothelioma Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Malignant Mesothelioma Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Malignant Mesothelioma Therapeutic Market Dynamics
  1. 2.1 Malignant Mesothelioma Therapeutic Industry Trends
  2. 2.2 Malignant Mesothelioma Therapeutic Industry Drivers
  3. 2.3 Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Therapeutic Industry Restraints
3 Malignant Mesothelioma Therapeutic Market by Company
  1. 3.1 Global Malignant Mesothelioma Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Malignant Mesothelioma Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Malignant Mesothelioma Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Malignant Mesothelioma Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Malignant Mesothelioma Therapeutic Company Product Type and Application
  6. 3.6 Global Malignant Mesothelioma Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Malignant Mesothelioma Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Malignant Mesothelioma Therapeutic Market by Type
  1. 4.1 Malignant Mesothelioma Therapeutic Type Introduction
  2. 4.1.1 Pemetrexed
  3. 4.1.2 Cisplatin
  4. 4.1.3 Others
  5. 4.2 Global Malignant Mesothelioma Therapeutic Sales Value by Type
  6. 4.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Malignant Mesothelioma Therapeutic Sales Value by Type (2021-2032)
  8. 4.2.3 Global Malignant Mesothelioma Therapeutic Sales Value Share by Type (2021-2032)
5 Malignant Mesothelioma Therapeutic Market by Application
  1. 5.1 Malignant Mesothelioma Therapeutic Application Introduction
  2. 5.1.1 Pleural Mesothelioma
  3. 5.1.2 Peritoneal Mesothelioma
  4. 5.1.3 Others
  5. 5.2 Global Malignant Mesothelioma Therapeutic Sales Value by Application
  6. 5.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Malignant Mesothelioma Therapeutic Sales Value by Application (2021-2032)
  8. 5.2.3 Global Malignant Mesothelioma Therapeutic Sales Value Share by Application (2021-2032)
6 Malignant Mesothelioma Therapeutic Regional Value Analysis
  1. 6.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Malignant Mesothelioma Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Malignant Mesothelioma Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Malignant Mesothelioma Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Malignant Mesothelioma Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Malignant Mesothelioma Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Malignant Mesothelioma Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Malignant Mesothelioma Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Malignant Mesothelioma Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Malignant Mesothelioma Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Malignant Mesothelioma Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Malignant Mesothelioma Therapeutic Country-level Value Analysis
  1. 7.1 Global Malignant Mesothelioma Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Malignant Mesothelioma Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Malignant Mesothelioma Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Malignant Mesothelioma Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Malignant Mesothelioma Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Malignant Mesothelioma Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Malignant Mesothelioma Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Malignant Mesothelioma Therapeutic Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Malignant Mesothelioma Therapeutic Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Malignant Mesothelioma Therapeutic Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Ono Pharmaceutical
  44. 8.8.1 Ono Pharmaceutical Company Information
  45. 8.8.2 Ono Pharmaceutical Business Overview
  46. 8.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
  48. 8.8.5 Ono Pharmaceutical Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Malignant Mesothelioma Therapeutic Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Fresenius Kabi
  56. 8.10.1 Fresenius Kabi Company Information
  57. 8.10.2 Fresenius Kabi Business Overview
  58. 8.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
  60. 8.10.5 Fresenius Kabi Recent Developments
  61. 8.11 Sun Pharmaceuticals
  62. 8.11.1 Sun Pharmaceuticals Company Information
  63. 8.11.2 Sun Pharmaceuticals Business Overview
  64. 8.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
  66. 8.11.5 Sun Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst